Trial · NCT04579393
Outcomes20
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 20
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With at Least 1 Serious Adverse Event | Day 29 | Intention-to-treat analysis | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Sustained Recoveries Defined by Ordinal Scale Score of 3 or Less | day 29 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Participants Who Progress to Mechanical Ventilation | day 29 | Participants who were not receiving mechanical ventilation at baseline | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Cumulative Clinical Endpoint of Death | day 14, day 28, day 60 | Intention-to-treat analysis | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Grade 3 and 4 Adverse Events Through Day 60 | Day 60 | Intention-to-treat analysis | Adverse Events | NUMBER |
| SECONDARY | Participant Score on Ordinal Scale | Day 15, Day 29 | intent to treat analysis | score on a scale | MEDIAN |
| SECONDARY | Change in C-Reactive Protein Levels From Baseline | Day 3, Day 5, Day 8, Day 11, Day 15, Day 29 | Intent to treat analysis. 58 patients (29 in each group) provided research samples for at least one time-point since baseline except for one patient who did not take any study drug and withdrew consent after enrollment. | mg/L (milligrams per liter) | MEDIAN |
| SECONDARY | Change in Fibrinogen Levels From Baseline. | Day 3, Day 5, Day 8, Day 11, Day 15, Day 29 | Intent to treat analysis. 58 patients (29 in each group) provided research samples for at least one time-point since baseline except for one patient who did not take any study drug and withdrew consent after enrollment. | mg/dL (milligrams per decilitre) | MEDIAN |
| SECONDARY | Change in D-Dimer Levels From Baseline | Day 3, Day 5, Day 8, Day 11, Day 15, Day 29 | Intent to treat analysis. 58 patients (29 in each group) provided research samples for at least one time-point since baseline except for one patient who did not take any study drug and withdrew consent after enrollment. | mcg/mL (microgram per milliliter) | MEDIAN |
| SECONDARY | Change in Ferritin Levels From Baseline | Day 3, Day 5, Day 8, Day 11, Day 15, Day 29 | Intent to treat analysis. 58 patients (29 in each group) provided research samples for at least one time-point since baseline except for one patient who did not take any study drug and withdrew consent after enrollment. | mcg/L (micrograms per liter) | MEDIAN |
| SECONDARY | Change in Interleukin 6 (IL6) Levels From Baseline | Day 3, Day 5, Day 8, Day 11, Day 15, Day 29 | Intent to treat analysis. 58 patients (29 in each group) provided research samples for at least one time-point since baseline except for one patient who did not take any study drug and withdrew consent after enrollment. | pg/mL (picograms per milliliter) | MEDIAN |
| SECONDARY | Median Days Participants Were Admitted to Intensive Care Unit | Day 29 | Participants admitted to Intensive Care Unit | Days | MEDIAN |
| SECONDARY | Relative Change in SpO2/FiO2 Ratio | Day 3, Day 5, Day 8, Day 11, Day 15, Day 29 | Only SpO2/FiO2 ratio is available as PaO2 was not consistently measured. Intent to treat analysis. 58 patients (29 in each group) provided research samples for at least one time-point since baseline except for one patient who did not take any study drug and withdrew consent after enrollment. | SpO2/FiO2 ratio | MEDIAN |
| SECONDARY | Change in SOFA Score From Baseline | Day 3, Day 5, Day 8, Day 11, Day 15, Day 29 | Intent to treat analysis. 58 patients (29 in each group) provided research samples for at least one time-point since baseline except for one patient who did not take any study drug and withdrew consent after enrollment. | score on a SOFA scale | MEDIAN |
| SECONDARY | Median Days on Participants Received Supplemental Oxygen | day 29 | days | MEDIAN | |
| SECONDARY | The Number of Participants That Experienced Acute Renal Failure | day 29 | Intent to treat analysis | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants That Experienced a Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE) | day 29 | Intent to Treat Analysis. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Change in Absolute Lymphocyte Count Levels From Baseline | Day 3, Day 5, Day 8, Day 11, Day 15, Day 29 | Intent to treat analysis. 58 patients (29 in each group) provided research samples for at least one time-point since baseline except for one patient who did not take any study drug and withdrew consent after enrollment. | thousand cells per microliter | MEDIAN |
| SECONDARY | Change in Absolute Neutrophil Count Levels From Baseline | Day 3, Day 5, Day 8, Day 11, Day 15, Day 29 | Intent to treat analysis. 58 patients (29 in each group) provided research samples for at least one time-point since baseline except for one patient who did not take any study drug and withdrew consent after enrollment. | thousand cells per microliter | MEDIAN |
| SECONDARY | Change in Platelet Count Levels From Baseline | Day 3, Day 5, Day 8, Day 11, Day 15, Day 29 | Intent to treat analysis. 58 patients (29 in each group) provided research samples for at least one time-point since baseline except for one patient who did not take any study drug and withdrew consent after enrollment. | thousand cells per microliter | MEDIAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04579393/outcomes